Download MendeleyDiscovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.
Heinrich, T., Seenisamy, J., Blume, B., Bomke, J., Calderini, M., Eckert, U., Friese-Hamim, M., Kohl, R., Lehmann, M., Leuthner, B., Musil, D., Rohdich, F., Zenke, F.T.(2019) J Med Chem 62: 5025-5039
- PubMed: 30939017
- DOI: https://doi.org/10.1021/acs.jmedchem.9b00041
- Primary Citation of Related Structures:
6QED, 6QEF, 6QEG, 6QEH, 6QEI, 6QEJ - PubMed Abstract:
Co- and post-translational processing are crucial maturation steps to generate functional proteins. MetAP-2 plays an important role in this process, and inhibition of its proteolytic activity has been shown to be important for angiogenesis and tumor growth, suggesting that small-molecule inhibitors of MetAP-2 may be promising options for the treatment of cancer. This work describes the discovery and structure-based hit optimization of a novel MetAP-2 inhibitory scaffold. Of critical importance, a cyclic tartronic diamide coordinates the MetAP-2 metal ion in the active site while additional side chains of the molecule were designed to occupy the lipophilic methionine side chain recognition pocket as well as the shallow cavity at the opening of the active site. The racemic screening hit from HTS campaign 11a was discovered with an enzymatic IC 50 of 150 nM. The resynthesized eutomer confirmed this activity and inhibited HUVEC proliferation with an IC 50 of 1.9 μM. Its structural analysis revealed a sophisticated interaction pattern of polar and lipophilic contacts that were used to improve cellular potency to an IC 50 of 15 nM. In parallel, the molecular properties were optimized on plasma exposure and antitumor efficacy which led to the identification of advanced lead 21.
Organizational Affiliation:
Merck Healthcare, Merck KGaA , Frankfurter Str. 250 , 64293 Darmstadt , Germany.
